ArticleMolecular biology reports2026
Expression patterns of ANRIL and GAS-5 and genetic variants in breast cancer.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the most malignancy diagnosed cancer worldwide. Antisense non-coding RNA(ANRIL) and Growth arrest specific-5(GAS-5) are types of Long non-coding RNAs(lncRNAs) that are essential regulators for BC development. Several single nucleotide polymorphisms (SNPs) in ANRIL and GAS-5 genes are associated with BC pathophysiology. AIM OF WORK: To measure levels of ANRIL and GAS-5 in patients with BC compared to controls. Also, investigate the distribution of SNP (rs11515) and (rs145204276) genotypes with the clinic-pathological parameters of patients. PATIENTS AND
methodsThirty-five BC patients and 20 healthy-matched age individuals were enrolled in this study. Real-time PCR (RT-qPCR) for relative quantitation of gene expression levels of ANRIL and GAS-5 was used.
resultsANRIL level was upregulated in patients group with median and interquartile (IQR) of 6.0(12.65). Meanwhile, GAS-5 was downregulated 0.46(0.58) with p < 0.0001 and P = 0.006 respectively between BC patients and controls. For ANRIL (rs11515), the distribution of ‘CG’ genotype was the majority in both groups versus ‘CC’ and ‘GG’ genotypes. While for GAS-5(rs145204276), ‘ins/ins’ genotype was more frequent in BC group. For controls, ‘ins/ins’ and ‘ins/del’ genotypes were the most followed by ‘del/del’ genotype. A significant difference was detected between the two groups as regards to ‘ins/ins’ genotype (p < 0.0001). ANRIL levels tended to decrease with the severity of the stage across all genotypes. While GAS-5 tended to increase with the severity across polymorphisms. There was a positive correlation between levels of biomarkers (ANRIL and GAS-5) ( (r = 0.497,p = 0.0024).
conclusionThe association of ANRIL and GAS-5 with genotype polymorphism suggests a potential link between genotype variations, biomarkers expression and disease progression.
Indexed as
Identifiers
41790366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.